VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study
I'm PortAI, I can summarize articles.
VolitionRx Ltd. has unveiled a new liquid biopsy method, Capture-Seq™, achieving 100% sensitivity and specificity in detecting cancer in a study of 70 individuals. The method analyzes ultrashort transcription factor-bound DNA in plasma, showing promise for early-stage disease detection. Results are available in a preprint but not yet validated in larger studies. The technology may expand VolitionRX's Nu.Q® portfolio.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments